A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

What Was Tested

This registered phase 4 trial tested Semaglutide and Liraglutide.

The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.

These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds.

The study will also look at how weight loss affects physical functioning, quality of life and ability to work.

It had two arms (groups): Semaglutide (experimental) and Other anti-obesity medication (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 500 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m\^2). Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.

The full record lists 2 inclusion and 5 exclusion criteria; among the exclusions: known or suspected hypersensitivity or contraindications to wegovy or related products according to the label; history of type 1 or type 2 diabetes mellitus.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Semaglutide study did not mask who received what.

It started in 2023-01-19 with completion listed for 2024-11-27.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 8 secondary outcomes, for example Percentage Change in Body Weight, Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain, Percentage of Days Covered (PDC) by Study Product and Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide and Liraglutide in 500 people.

With 500 participants it is a large trial for this field.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Semaglutide compound page and the Liraglutide compound page, all human trials.